ME Therapeutics Holdings Inc
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$88.65M
-0.04
ME Therapeutics Holdings, Inc. provides biotechnology and pharmaceutical services. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2023-10-12. The Company’s focus is on overcoming the suppressive effects of a class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. The firm has initiated design and testing of two new mRNA-based cancer therapeutic drug candidates.
ME Therapeutics Holdings, Inc. provides biotechnology and pharmaceutical services. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2023-10-12. The Company’s focus is on overcoming the suppressive effects of a class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. The firm has initiated design and testing of two new mRNA-based cancer therapeutic drug candidates.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.